{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:02Z","timestamp":1740144062156,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40262-022-01201-7","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T11:39:53Z","timestamp":1673955593000},"page":"113-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of an Intrauterine Device Releasing Both Indomethacin and Levonorgestrel During the First Months of Use: Pharmacokinetic Characterization in Healthy Women"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-2630","authenticated-orcid":false,"given":"Birte Maria","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manja","family":"Ahola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lueder M.","family":"Fels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Lindenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyrki","family":"Pihlaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"issue":"21","key":"1201_CR1","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1110855","volume":"366","author":"B Winner","year":"2012","unstructured":"Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998\u20132007.","journal-title":"N Engl J Med"},{"issue":"5","key":"1201_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.contraception.2011.01.021","volume":"83","author":"J Trussell","year":"2011","unstructured":"Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397\u2013404.","journal-title":"Contraception"},{"issue":"5","key":"1201_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/AOG.0b013e31821188ad","volume":"117","author":"JF Peipert","year":"2011","unstructured":"Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105\u201313.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"1201_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13625187.2018.1535653","volume":"23","author":"A Agostini","year":"2018","unstructured":"Agostini A, Godard C, Laurendeau C, Benmahmoud Zoubir A, Lafuma A, Levy-Bachelot L, et al. Two-year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database. Eur J Contracept Reprod Health Care. 2018;23(6):421\u20136.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"6","key":"1201_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/13625187.2020.1815008","volume":"25","author":"B Hofmann","year":"2020","unstructured":"Hofmann B, Apter D, Bitzer J, Reinecke I, Serrani M, H\u00f6chel J, et al. Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route. Eur J Contracept Reprod Health Care. 2020;25(6):417\u201326.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"1201_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/humupd\/dmq026","volume":"17","author":"PD Blumenthal","year":"2011","unstructured":"Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011;17(1):121\u201337.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"1201_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1097\/AOG.0000000000001094","volume":"126","author":"ML Kavanaugh","year":"2015","unstructured":"Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009\u20132012. Obstet Gynecol. 2015;126(5):917\u201327.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"1201_CR8","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1093\/humrep\/dev221","volume":"30","author":"L Bahamondes","year":"2015","unstructured":"Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30(11):2527\u201338.","journal-title":"Hum Reprod"},{"issue":"1","key":"1201_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/13625187.2013.853034","volume":"19","author":"E Weisberg","year":"2014","unstructured":"Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care. 2014;19(1):5\u201314.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"5","key":"1201_CR10","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/humrep\/13.5.1210","volume":"13","author":"HO Critchley","year":"1998","unstructured":"Critchley HO, Wang H, Kelly RW, Gebbie AE, Glasier AF. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 1998;13(5):1210\u20137.","journal-title":"Hum Reprod"},{"key":"1201_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0010-7824(87)90057-6","volume":"36","author":"BL Sheppard","year":"1987","unstructured":"Sheppard BL. Endometrial morphological changes in IUD users: a review. Contraception. 1987;36:1\u201310.","journal-title":"Contraception"},{"issue":"1","key":"1201_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.fertnstert.2016.02.036","volume":"106","author":"D Apter","year":"2016","unstructured":"Apter D, Briggs P, Tuppurainen M, Grunert J, Lukkari-Lax E, Rybowski S, Gemzell-Danielsson K. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril. 2016;106(1):151-7.e5.","journal-title":"Fertil Steril"},{"issue":"3","key":"1201_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.fertnstert.2011.12.003","volume":"97","author":"K Gemzell-Danielsson","year":"2012","unstructured":"Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97(3):616-22.e1-3.","journal-title":"Fertil Steril"},{"issue":"6","key":"1201_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.contraception.2016.02.004","volume":"93","author":"K Gemzell-Danielsson","year":"2016","unstructured":"Gemzell-Danielsson K, Buhling KJ, Dermout SM, Lukkari-Lax E, Montegriffo E, Apter D. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents. Contraception. 2016;93(6):507\u201312.","journal-title":"Contraception"},{"key":"1201_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/13691050902919093","volume":"11","author":"JE Bradley","year":"2009","unstructured":"Bradley JE, Alam ME, Shabnam F, Beattie TSH. Blood, men and tears: keeping IUDs in place in Bangladesh. Cult Health Sex. 2009;11:543\u201358.","journal-title":"Cult Health Sex"},{"key":"1201_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/AOG.0000000000001655","volume":"128","author":"JA Higgins","year":"2016","unstructured":"Higgins JA, Sanders JN, Palta M, Turok DK. Women\u2019s sexual function, satisfaction, and perceptions after starting long-acting reversible contraceptives. Obstet Gynecol. 2016;128:1143\u201351.","journal-title":"Obstet Gynecol"},{"key":"1201_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12978-018-0561-0","volume":"15","author":"CB Polis","year":"2018","unstructured":"Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women\u2019s responses to contraceptive-induced menstrual bleeding changes. Reprod Health. 2018;15:114.","journal-title":"Reprod Health"},{"key":"1201_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jadohealth.2015.05.001","volume":"57","author":"EO Schmidt","year":"2015","unstructured":"Schmidt EO, James A, Curran KM, Peipert JF, Madden T. Adolescent experiences with intrauterine devices: a qualitative study. J Adolesc Health. 2015;57:381\u20136.","journal-title":"J Adolesc Health"},{"issue":"11","key":"1201_CR19","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1111\/jog.13441","volume":"43","author":"NM Carvalho","year":"2017","unstructured":"Carvalho NM, Chou V, Modesto W, Margatho D, Garcia EAL, Bahamondes L. Relationship between user satisfaction with the levonorgestrel-releasing intrauterine system and bleeding patterns. J Obstet Gynaecol Res. 2017;43(11):1732\u20137.","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"1201_CR20","doi-asserted-by":"publisher","first-page":"e0199724","DOI":"10.1371\/journal.pone.0199724","volume":"13","author":"JN Sanders","year":"2018","unstructured":"Sanders JN, Adkins DE, Kaur S, Storck K, Gawron LM, Turok DK. Bleeding, cramping, and satisfaction among new copper IUD users: a prospective study. PLoS ONE. 2018;13(11):e0199724.","journal-title":"PLoS ONE"},{"key":"1201_CR21","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/01.AOG.0000435452.86108.59","volume":"122","author":"DS Grunloh","year":"2013","unstructured":"Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122:1214\u201321.","journal-title":"Obstet Gynecol"},{"key":"1201_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0149-2918(96)80187-1","volume":"18","author":"JE Davie","year":"1996","unstructured":"Davie JE, Walling MR, Mansour DJ, Bromham D, Kishen M, Fowler P. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther. 1996;18:150\u20139.","journal-title":"Clin Ther"},{"key":"1201_CR23","first-page":"CD001751","volume":"7","author":"J Marjoribanks","year":"2015","unstructured":"Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;7:CD001751.","journal-title":"Cochrane Database Syst Rev"},{"key":"1201_CR24","first-page":"CD006034","volume":"4","author":"DA Grimes","year":"2006","unstructured":"Grimes DA, Hubacher D, Lopez LM, Schulz KF. Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. Cochrane Database Syst Rev. 2006;4:CD006034.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1201_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.contraception.2012.09.006","volume":"87","author":"EM Godfrey","year":"2013","unstructured":"Godfrey EM, Folger SG, Jeng G, Jamieson DJ, Curtis KM. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception. 2013;87(5):549\u201366.","journal-title":"Contraception"},{"issue":"1","key":"1201_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijgo.2013.02.016","volume":"122","author":"X Hu","year":"2013","unstructured":"Hu X, Li L, Zou Y, Wu S. A multicenter comparative study of UCu200, TCu380A, and medicated \u03b3-IUD devices inserted immediately after vacuum aspiration. Int J Gynaecol Obstet. 2013;122(1):65\u20139.","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"1201_CR27","first-page":"496","volume":"93","author":"LY Wang","year":"2013","unstructured":"Wang LY, Li SZ, Wu SY, Zhao YH, Wang Y. A random control study of indomethacin-containing MYCu intrauterine contraceptive device for 60 months [in Chinese]. Zhonghua Yi Xue Za Zhi. 2013;93(7):496\u20139.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1201_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0002-9343(98)00091-6","volume":"104","author":"B Cryer","year":"1998","unstructured":"Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413\u201321.","journal-title":"Am J Med"},{"key":"1201_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0223-5234(01)01197-7","volume":"36","author":"G Dannhardt","year":"2001","unstructured":"Dannhardt G, Kiefer W. Cyclooxygenase inhibitors \u2013 current status and future prospects. Eur J Med Chem. 2001;36:109\u201326.","journal-title":"Eur J Med Chem"},{"key":"1201_CR30","unstructured":"Jaydess Summary of Product Characteristics. Bayer. July 2020. https:\/\/www.medicines.org.uk\/emc\/product\/5297\/smpc. Accessed Oct 2021."},{"key":"1201_CR31","unstructured":"European Medicines Agency. Guideline on Bioanalytical Method Validation. European Medicines Agency; 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 27 Sep 2021."},{"key":"1201_CR32","unstructured":"US FDA. FDA CDER \u2013 Bioanalytical Method Validation \u2013 Guidance for Industry. US FDA; 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 27 Sep 2021."},{"key":"1201_CR33","unstructured":"European Medicines Agency, GCP Inspectors Working Group. Reflection Paper for Laboratories that Perform the Analysis or Evaluation of Clinical Trial Samples. February 28, 2012. European Medicines Agency; 2012. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/reflection-paper-laboratories-perform-analysis-evaluation-clinical-trial-samples_en.pdf. Accessed 27 Sep 2021."},{"key":"1201_CR34","unstructured":"Organisation for Economic Co-operation and Development. OECD Principles on Good Laboratory Practice (ENV\/MC\/CHEM(98)17). Organisation for Economic Co-operation and Development; 1997. https:\/\/one.oecd.org\/document\/ENV\/MC\/CHEM(98)17\/en\/pdf. Accessed 27 Sept 2021."},{"key":"1201_CR35","unstructured":"International Council for Harmonisation. ICH Harmonised Tripartite Guideline, Guideline for Good Clinical Practice E6 (R2). ICH. 2016. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 27 Sep 2021."},{"key":"1201_CR36","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","volume":"52","author":"LA Garc\u00eda Rodr\u00edguez","year":"2008","unstructured":"Garc\u00eda Rodr\u00edguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52:1628\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"1201_CR37","unstructured":"Indomethacin Summary of Product Characteristics. Ratiopharm. May 2013. https:\/\/s3.eu-central-1.amazonaws.com\/prod-cerebro-ifap\/media_all\/48289.pdf. Accessed Jul 2021."},{"key":"1201_CR38","unstructured":"INDOCIN prescribing information. March 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/016059s100lbl.pdf. Accessed Oct 2021."},{"key":"1201_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/13625187.2021.1975269","volume":"27","author":"C Bastianelli","year":"2022","unstructured":"Bastianelli C, Farris M, Rosato E, Varliero F, Del Savio MC, Facchinetti F, Grandi G. The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study. Eur J Contracept Reprod Health Care. 2022;27:16\u201322.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"12","key":"1201_CR40","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1080\/09513590.2020.1802420","volume":"36","author":"G Grandi","year":"2020","unstructured":"Grandi G, De Fata R, Varliero F, Del Savio MC, Facchinetti F. Contemporary prescriptions pattern of different dose levonorgestrel-releasing intrauterine systems in an Italian service for family planning. Gynecol Endocrinol. 2020;36(12):1086\u20139.","journal-title":"Gynecol Endocrinol"},{"key":"1201_CR41","first-page":"0805","volume":"2012","author":"K Duckitt","year":"2012","unstructured":"Duckitt K, Collins S. Menorrhagia. BMJ Clin Evid. 2012;2012:0805.","journal-title":"BMJ Clin Evid"},{"issue":"6","key":"1201_CR42","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/ajo.12534","volume":"56","author":"D Bateson","year":"2016","unstructured":"Bateson D, Harvey C, Trinh L, Stewart M, Black KI. User characteristics, experiences and continuation rates of copper intrauterine device use in a cohort of Australian women. Aust N Z J Obstet Gynaecol. 2016;56(6):655\u201361.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"1201_CR43","unstructured":"Jaydess Prescribing Information. Bayer. July 2021. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Skyla_PI.pdf. Accessed Oct 2021."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01201-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01201-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01201-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T16:05:54Z","timestamp":1675440354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01201-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01201-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"12 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original phase II study was funded by Bayer AG, Berlin, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Birte Maria Hofmann, Lueder M. Fels, Stefan Klein and Bernhard Lindenthal are employees of Bayer AG, Berlin. Germany. Manja Ahola and Jyrki Pihlaja are employees of Bayer OY, Turku, Finland.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The original phase II study was registered at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03562624, clinical trial registration number NCT03562624. Approvals were obtained from the Institutional Review Boards and Independent Ethics Committees for each participating center and the study was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written, informed consent prior to study start.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Upon request from qualified scientific and medical researchers, Bayer (the study sponsor) will share patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials, as necessary for conducting legitimate research. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Data access will be granted to anonymized patient-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Birte M. Hofmann, Lueder Fels, Stefan Klein, and Bernhard Lindenthal participated in the development of the study design, and analysis and critical discussion of data. Manja Ahola and Jyrki Pihlaja participated in the conduct of the in vitro characterization analyses and critical interpretation of data outputs. Michal Zvolanek participated in critical discussion of data. All authors contributed to the initial manuscript draft and critically appraised all subsequent drafts. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}